DAWN Q2 2022 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$133,000

Operating Income

-$37M

Net Income

-$37M

EPS (Diluted)

$-0.60

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$404M

Total Liabilities

$13M

Stockholders' Equity

$391M

Cash & Equivalents

$389M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$133,000	-$49,000	-171.4%
Operating Income	-$37M	-$15M	-137.8%
Net Income	-$37M	-$14M	-155.8%